{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:41:49Z","timestamp":1783568509150,"version":"3.55.0"},"reference-count":76,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Emerging data suggest that benzodiazepines are not appropriate for patients in the long-term management of schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted on studies published on the topic of benzodiazepines and schizophrenia from 2004 to 2024. The search returned more than 3000 results of which 27 were relevant to include in this scoping review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The publications identified for this review spanned benzodiazepines\u2019 negative impact on mortality, hospitalizations, brain volume changes, cognition, global functioning, and quality of life. There were also publications identified to evaluate the current evidence for use in schizophrenia as well as related conditions, such as tardive dyskinesia, akathisia, and catatonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Based on the currently available guidelines, there seems to be a lack of a clear stance against the regular use of benzodiazepines in schizophrenia. These organizations should be more straightforward about the specific potential uses and risks associated with benzodiazepine use in schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.9740\/mhc.2025.12.315","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:57:48Z","timestamp":1765274268000},"page":"315-322","source":"Crossref","is-referenced-by-count":1,"title":["Benzodiazepine use in schizophrenia: A review of the literature"],"prefix":"10.9740","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-1094","authenticated-orcid":true,"given":"Chris","family":"Noel","sequence":"first","affiliation":[{"name":"(Corresponding author) Associate Professor of Pharmacy Practice, St John Fisher University, Rochester, New York, cnoel@sjfc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0344-6356","authenticated-orcid":true,"given":"Colleen","family":"Maclay","sequence":"additional","affiliation":[{"name":"Pharmacy Student, St John Fisher University, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"11","key":"i2168-9709-15-6-315-b01","series-title":"Drugs","first-page":"1273","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo M,\nTiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273-84. DOI: 10.1007\/s40265-021-01556-4"},{"issue":"5","key":"i2168-9709-15-6-315-b02","series-title":"JAMA Psychiatry","first-page":"499","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","unstructured":"Tiihonen J,\nTaipale H,\nMeht\u00e4l\u00e4 J,\nVattulainen P,\nCorrell CU,\nTanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. DOI: 10.1001\/jamapsychiatry.2018.4320"},{"issue":"2","key":"i2168-9709-15-6-315-b03","series-title":"J Clin Psychiatry","first-page":"103","article-title":"Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study","volume":"71","author":"Baandrup","year":"2010","unstructured":"Baandrup L,\nGasse C,\nJensen VD,\nGlenthoj BY,\nNordentoft M,\nLublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103-8. DOI: 10.4088\/JCP.08m04818yel"},{"issue":"5","key":"i2168-9709-15-6-315-b04","series-title":"Arch Gen Psychiatry","first-page":"476","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","unstructured":"Tiihonen J,\nSuokas JT,\nSuvisaari JM,\nHaukka J,\nKorhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-83. DOI: 10.1001\/archgenpsychiatry.2011.1532"},{"issue":"6","key":"i2168-9709-15-6-315-b05","series-title":"Amer J Psychiatry","first-page":"600","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","unstructured":"Tiihonen J,\nMittendorfer-Rutz E,\nTorniainen M,\nAlexanderson K,\nTanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Amer J Psychiatry. 2016;173(6):600-6. DOI: 10.1176\/appi.ajp.2015.15050618"},{"issue":"5","key":"i2168-9709-15-6-315-b06","series-title":"J Clin Psychiatry","first-page":"661","article-title":"Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study","volume":"77","author":"Fontanella","year":"2016","unstructured":"Fontanella CA,\nCampo JV,\nPhillips GS,\nHiance-Steelesmith DL,\nSweeney HA,\nTam K, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry. 2016;77(5):661-7. DOI: 10.4088\/JCP.15m10271"},{"issue":"4","key":"i2168-9709-15-6-315-b07","series-title":"Early Interv Psychiatry","first-page":"902","article-title":"Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort","volume":"13","author":"Str\u00e5lin","year":"2019","unstructured":"Str\u00e5lin P,\nHetta J. Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort. Early Interv Psychiatry. 2019;13(4):902-7. DOI: 10.1111\/eip.12697"},{"issue":"11","key":"i2168-9709-15-6-315-b08","series-title":"Psychopharmacology (Berl","first-page":"3329","article-title":"Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study","volume":"235","author":"Cheng","year":"2018","unstructured":"Cheng S-Y,\nChen WY,\nLiu HC,\nYang TW,\nPan CH,\nYang SY, et al. Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study. Psychopharmacology (Berl). 2018;235(11):3329-38. DOI: 10.1007\/s00213-018-5039-9"},{"key":"i2168-9709-15-6-315-b09","series-title":"Front Psychiatry","first-page":"1071079","article-title":"Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients","volume":"13","author":"Yang","year":"2023","unstructured":"Yang Y,\nKong D,\nLi Q,\nChen W,\nZhao G,\nTan X, et al. Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients. Front Psychiatry. 2023;13:1071079. DOI: 10.3389\/fpsyt.2022.1071079"},{"key":"i2168-9709-15-6-315-b10","series-title":"Schizophr Res","first-page":"35","article-title":"Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia","volume":"248","author":"Str\u00f8mme","year":"2022","unstructured":"Str\u00f8mme MF,\nBartz-Johannesen C,\nKroken RA,\nMehlum L,\nJohnsen E. Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia. Schizophr Res. 2022;248:35-41. DOI: 10.1016\/j.schres.2022.07.014"},{"key":"i2168-9709-15-6-315-b11","series-title":"Neuropsychiatr Dis Treat","first-page":"3243","article-title":"Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study","volume":"12","author":"Takita","year":"2016","unstructured":"Takita Y,\nTakaesu Y,\nOno K,\nFutenma K,\nShimura A,\nMurakoshi A, et al. Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study. Neuropsychiatr Dis Treat. 2016;12:3243-7. DOI: 10.2147\/NDT.S118759"},{"key":"i2168-9709-15-6-315-b12","series-title":"Psychiatry Res Neuroimaging","first-page":"73","article-title":"Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia: the Northern Finland Birth Cohort 1966 study","volume":"266","author":"Huhtaniska","year":"2017","unstructured":"Huhtaniska S,\nJ\u00e4\u00e4skel\u00e4inen E,\nHeikka T,\nMoilanen JS,\nLehtiniemi H,\nTohka J, et al. Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia: the Northern Finland Birth Cohort 1966 study. Psychiatry Res Neuroimaging. 2017;266:73-82. DOI: 10.1016\/j.pscychresns.2017.05.009"},{"key":"i2168-9709-15-6-315-b13","series-title":"Psychiatry Res Neuroimaging","first-page":"43","article-title":"Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses\u2014systematic reviews and birth cohort study","volume":"281","author":"Huhtaniska","year":"2018","unstructured":"Huhtaniska S,\nKorkala I,\nHeikka T,\nBj\u00f6rnholm L,\nLehtiniemi H,\nHulkko AP, et al. Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses\u2014systematic reviews and birth cohort study. Psychiatry Res Neuroimaging. 2018;281:43-52. DOI: 10.1016\/j.pscychresns.2018.08.015"},{"issue":"2","key":"i2168-9709-15-6-315-b14","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"300","article-title":"Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic","volume":"36","author":"Kitajima","year":"2012","unstructured":"Kitajima R,\nMiyamoto S,\nTenjin T,\nOjima K,\nOgino S,\nMiyake N, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):300-6. DOI: 10.1016\/j.pnpbp.2011.11.008"},{"issue":"2","key":"i2168-9709-15-6-315-b15","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"163","article-title":"Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo","volume":"267","author":"Baandrup","year":"2017","unstructured":"Baandrup L,\nFagerlund B,\nGlenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163-71. DOI: 10.1007\/s00406-016-0711-8"},{"issue":"1","key":"i2168-9709-15-6-315-b16","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"17","article-title":"Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set","volume":"268","author":"Fond","year":"2018","unstructured":"Fond G,\nBerna F,\nBoyer L,\nGodin O,\nBrunel L,\nAndrianarisoa M, et al. Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci. 2018;268(1):17-26. DOI: 10.1007\/s00406-017-0787-9"},{"key":"i2168-9709-15-6-315-b17","series-title":"Eur Psychiatry","first-page":"50","article-title":"Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966","volume":"45","author":"Hulkko","year":"2017","unstructured":"Hulkko AP,\nMurray GK,\nMoilanen J,\nHaapea M,\nRannikko I,\nJones PB, et al. Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966. Eur Psychiatry. 2017;45:50-8. DOI: 10.1016\/j.eurpsy.2017.06.004"},{"issue":"3","key":"i2168-9709-15-6-315-b18","series-title":"Clin Neuropharmacol","first-page":"89","article-title":"Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders\u2014associations with cognition and global functioning","volume":"44","author":"Savi\u0107","year":"2021","unstructured":"Savi\u0107 B,\nJeroti\u0107 S,\nRisti\u0107 I,\nZebi\u0107 M,\nJovanovi\u0107 N,\nRusso M, et al. Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders\u2014associations with cognition and global functioning. Clin Neuropharmacol. 2021;44(3):89-93. DOI: 10.1097\/WNF.0000000000000442"},{"issue":"3","key":"i2168-9709-15-6-315-b19","series-title":"PCN Rep","first-page":"e42","article-title":"Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia","volume":"1","author":"Oyama","year":"2022","unstructured":"Oyama H,\nOda K,\nMatsuo R. Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia. PCN Rep. 2022;1(3):e42. DOI: 10.1002\/pcn5.42"},{"key":"i2168-9709-15-6-315-b20","series-title":"Schizophr Res","first-page":"118","article-title":"Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia","volume":"266","author":"M\u00e4kipelto","year":"2024","unstructured":"M\u00e4kipelto V,\nTuulio-Henriksson A,\nHakulinen C,\nNiemel\u00e4 S,\nL\u00e4hteenvuo M,\nWegelius A, et al. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia. Schizophr Res. 2024;266:118-26. DOI: 10.1016\/j.schres.2024.02.025"},{"issue":"11","key":"i2168-9709-15-6-315-b21","series-title":"Cochrane Database Syst Rev","first-page":"CD006391","article-title":"Benzodiazepines for schizophrenia","volume":"11","author":"Dold","year":"2012","unstructured":"Dold M,\nLi C,\nTardy M,\nKhorsand V,\nGillies D,\nLeucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11(11):CD006391. DOI: 10.1002\/14651858.CD006391.pub2"},{"issue":"9","key":"i2168-9709-15-6-315-b22","series-title":"Eur Neuropsychopharmacol","first-page":"1023","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","unstructured":"Dold M,\nLi C,\nGillies D,\nLeucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol. 2013;23(9):1023-33. DOI: 10.1016\/j.euroneuro.2013.03.001"},{"issue":"12","key":"i2168-9709-15-6-315-b23","series-title":"Cochrane Database Syst Rev","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"12","author":"Zaman","year":"2017","unstructured":"Zaman H,\nSampson SJ,\nBeck AL,\nSharma T,\nClay FJ,\nSpyridi S, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017;12(12):CD003079. DOI: 10.1002\/14651858.CD003079.pub4"},{"key":"i2168-9709-15-6-315-b24","series-title":"Schizophr Bull","first-page":"sbae098","article-title":"Comparative efficacy and acceptability of treatment strategies for antipsychotic-induced akathisia: a systematic review and network meta-analysis","author":"Furukawa","year":"2024","unstructured":"Furukawa Y,\nImai K,\nTakahashi Y,\nEfthimiou O,\nLeucht S. Comparative efficacy and acceptability of treatment strategies for antipsychotic-induced akathisia: a systematic review and network meta-analysis. Schizophr Bull. 2024:sbae098. DOI: 10.1093\/schbul\/sbae098"},{"issue":"6","key":"i2168-9709-15-6-315-b25","series-title":"J Clin Psychopharmacol","first-page":"403","article-title":"Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study","volume":"9","author":"Kutcher","year":"1989","unstructured":"Kutcher S,\nWilliamson P,\nMacKenzie S,\nMarton P,\nEhrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1989;9(6):403-6. PMID: 2574191"},{"issue":"3","key":"i2168-9709-15-6-315-b26","series-title":"Clin Neuropharmacol","first-page":"236","article-title":"A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia","volume":"17","author":"Pujalte","year":"1994","unstructured":"Pujalte D,\nBotta\u00ef T,\nHu\u00eb B,\nAlric R,\nPouget R,\nBlayac JP, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236-42. DOI: 10.1097\/00002826-199406000-00003"},{"issue":"1-3","key":"i2168-9709-15-6-315-b27","series-title":"Schizophr Res","first-page":"255","article-title":"Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset","volume":"169","author":"Berna","year":"2015","unstructured":"Berna F,\nMisdrahi D,\nBoyer L,\nAouizerate B,\nBrunel L,\nCapdevielle D, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015;169(1-3):255-61. DOI: 10.1016\/j.schres.2015.10.040"},{"issue":"1","key":"i2168-9709-15-6-315-b28","series-title":"Cochrane Database Syst Rev","first-page":"CD000205","article-title":"Benzodiazepines for antipsychotic-induced tardive dyskinesia","volume":"1","author":"Bergman","year":"2018","unstructured":"Bergman H,\nBhoopathi PS,\nSoares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000205. DOI: 10.1002\/14651858.CD000205.pub3"},{"issue":"8","key":"i2168-9709-15-6-315-b29","series-title":"Cochrane Database Syst Rev","first-page":"CD006570","article-title":"Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses","volume":"8","author":"Zaman","year":"2019","unstructured":"Zaman H,\nGibson RC,\nWalcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Cochrane Database Syst Rev. 2019;8(8):CD006570. DOI: 10.1002\/14651858.CD006570.pub3"},{"issue":"5","key":"i2168-9709-15-6-315-b30","series-title":"Neurology","first-page":"463","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R,\nFahn S,\nWeiner WJ,\nGronseth GS,\nSullivan KL,\nZesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-9. DOI: 10.1212\/WNL.0b013e31829d86b6. Erratum in: Neurology. 2013;81(22):1968. PMID: 23897874"},{"key":"i2168-9709-15-6-315-b31","series-title":"J Neurol Sci","first-page":"67","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R,\nJitkritsadakul O,\nFriedman JH,\nFahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75. DOI: 10.1016\/j.jns.2018.02.010"},{"issue":"4","key":"i2168-9709-15-6-315-b32","series-title":"J Psychopharmacol","first-page":"327","article-title":"Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology","volume":"37","author":"Rogers","year":"2023","unstructured":"Rogers JP,\nOldham MA,\nFricchione G,\nNorthoff G,\nEllen Wilson J,\nMann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327-69. DOI: 10.1177\/02698811231158232"},{"issue":"5","key":"i2168-9709-15-6-315-b33","series-title":"Aust N Z J Psychiatry","first-page":"410","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","unstructured":"Galletly C,\nCastle D,\nDark F,\nHumberstone V,\nJablensky A,\nKillackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-72. DOI: 10.1177\/0004867416641195"},{"issue":"9","key":"i2168-9709-15-6-315-b34","series-title":"Can J Psychiatry","first-page":"604","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","unstructured":"Remington G,\nAddington D,\nHoner W,\nIsmail Z,\nRaedler T,\nTeehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604-16. DOI: 10.1177\/0706743717720448"},{"issue":"1","key":"i2168-9709-15-6-315-b35","series-title":"J Psychopharmacol","first-page":"3","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","unstructured":"Barnes TR,\nDrake R,\nPaton C,\nCooper SJ,\nDeakin B,\nFerrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. DOI: 10.1177\/0269881119889296"},{"issue":"9","key":"i2168-9709-15-6-315-b36","series-title":"Am J Psychiatry","first-page":"868","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","unstructured":"Keepers GA,\nFochtmann LJ,\nAnzia JM,\nBenjamin S,\nLyness JM,\nMojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-72. DOI: 10.1176\/appi.ajp.2020.177901"},{"issue":"1","key":"i2168-9709-15-6-315-b37","series-title":"Harv Rev Psychiatry","first-page":"18","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","author":"Osser","year":"2013","unstructured":"Osser DN,\nRoudsari MJ,\nManschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013;21(1):18-40. DOI: 10.1097\/HRP.0b013e31827fd915"},{"issue":"1","key":"i2168-9709-15-6-315-b38","series-title":"Eur Psychiatry","first-page":"e57","article-title":"European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia","volume":"65","author":"Vita","year":"2022","unstructured":"Vita A,\nGaebel W,\nMucci A,\nSachs G,\nBarlati S,\nGiordano GM, et al. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65(1):e57. DOI: 10.1192\/j.eurpsy.2022.2315"},{"issue":"11","key":"i2168-9709-15-6-315-b01","series-title":"Drugs","first-page":"1273","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo M,\nTiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273-84. DOI: 10.1007\/s40265-021-01556-4"},{"issue":"5","key":"i2168-9709-15-6-315-b02","series-title":"JAMA Psychiatry","first-page":"499","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","unstructured":"Tiihonen J,\nTaipale H,\nMeht\u00e4l\u00e4 J,\nVattulainen P,\nCorrell CU,\nTanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. DOI: 10.1001\/jamapsychiatry.2018.4320"},{"issue":"2","key":"i2168-9709-15-6-315-b03","series-title":"J Clin Psychiatry","first-page":"103","article-title":"Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study","volume":"71","author":"Baandrup","year":"2010","unstructured":"Baandrup L,\nGasse C,\nJensen VD,\nGlenthoj BY,\nNordentoft M,\nLublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103-8. DOI: 10.4088\/JCP.08m04818yel"},{"issue":"5","key":"i2168-9709-15-6-315-b04","series-title":"Arch Gen Psychiatry","first-page":"476","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","unstructured":"Tiihonen J,\nSuokas JT,\nSuvisaari JM,\nHaukka J,\nKorhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-83. DOI: 10.1001\/archgenpsychiatry.2011.1532"},{"issue":"6","key":"i2168-9709-15-6-315-b05","series-title":"Amer J Psychiatry","first-page":"600","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","unstructured":"Tiihonen J,\nMittendorfer-Rutz E,\nTorniainen M,\nAlexanderson K,\nTanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Amer J Psychiatry. 2016;173(6):600-6. DOI: 10.1176\/appi.ajp.2015.15050618"},{"issue":"5","key":"i2168-9709-15-6-315-b06","series-title":"J Clin Psychiatry","first-page":"661","article-title":"Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study","volume":"77","author":"Fontanella","year":"2016","unstructured":"Fontanella CA,\nCampo JV,\nPhillips GS,\nHiance-Steelesmith DL,\nSweeney HA,\nTam K, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry. 2016;77(5):661-7. DOI: 10.4088\/JCP.15m10271"},{"issue":"4","key":"i2168-9709-15-6-315-b07","series-title":"Early Interv Psychiatry","first-page":"902","article-title":"Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort","volume":"13","author":"Str\u00e5lin","year":"2019","unstructured":"Str\u00e5lin P,\nHetta J. Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort. Early Interv Psychiatry. 2019;13(4):902-7. DOI: 10.1111\/eip.12697"},{"issue":"11","key":"i2168-9709-15-6-315-b08","series-title":"Psychopharmacology (Berl","first-page":"3329","article-title":"Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study","volume":"235","author":"Cheng","year":"2018","unstructured":"Cheng S-Y,\nChen WY,\nLiu HC,\nYang TW,\nPan CH,\nYang SY, et al. Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study. Psychopharmacology (Berl). 2018;235(11):3329-38. DOI: 10.1007\/s00213-018-5039-9"},{"key":"i2168-9709-15-6-315-b09","series-title":"Front Psychiatry","first-page":"1071079","article-title":"Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients","volume":"13","author":"Yang","year":"2023","unstructured":"Yang Y,\nKong D,\nLi Q,\nChen W,\nZhao G,\nTan X, et al. Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients. Front Psychiatry. 2023;13:1071079. DOI: 10.3389\/fpsyt.2022.1071079"},{"key":"i2168-9709-15-6-315-b10","series-title":"Schizophr Res","first-page":"35","article-title":"Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia","volume":"248","author":"Str\u00f8mme","year":"2022","unstructured":"Str\u00f8mme MF,\nBartz-Johannesen C,\nKroken RA,\nMehlum L,\nJohnsen E. Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia. Schizophr Res. 2022;248:35-41. DOI: 10.1016\/j.schres.2022.07.014"},{"key":"i2168-9709-15-6-315-b11","series-title":"Neuropsychiatr Dis Treat","first-page":"3243","article-title":"Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study","volume":"12","author":"Takita","year":"2016","unstructured":"Takita Y,\nTakaesu Y,\nOno K,\nFutenma K,\nShimura A,\nMurakoshi A, et al. Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study. Neuropsychiatr Dis Treat. 2016;12:3243-7. DOI: 10.2147\/NDT.S118759"},{"key":"i2168-9709-15-6-315-b12","series-title":"Psychiatry Res Neuroimaging","first-page":"73","article-title":"Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia: the Northern Finland Birth Cohort 1966 study","volume":"266","author":"Huhtaniska","year":"2017","unstructured":"Huhtaniska S,\nJ\u00e4\u00e4skel\u00e4inen E,\nHeikka T,\nMoilanen JS,\nLehtiniemi H,\nTohka J, et al. Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia: the Northern Finland Birth Cohort 1966 study. Psychiatry Res Neuroimaging. 2017;266:73-82. DOI: 10.1016\/j.pscychresns.2017.05.009"},{"key":"i2168-9709-15-6-315-b13","series-title":"Psychiatry Res Neuroimaging","first-page":"43","article-title":"Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses\u2014systematic reviews and birth cohort study","volume":"281","author":"Huhtaniska","year":"2018","unstructured":"Huhtaniska S,\nKorkala I,\nHeikka T,\nBj\u00f6rnholm L,\nLehtiniemi H,\nHulkko AP, et al. Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses\u2014systematic reviews and birth cohort study. Psychiatry Res Neuroimaging. 2018;281:43-52. DOI: 10.1016\/j.pscychresns.2018.08.015"},{"issue":"2","key":"i2168-9709-15-6-315-b14","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"300","article-title":"Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic","volume":"36","author":"Kitajima","year":"2012","unstructured":"Kitajima R,\nMiyamoto S,\nTenjin T,\nOjima K,\nOgino S,\nMiyake N, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):300-6. DOI: 10.1016\/j.pnpbp.2011.11.008"},{"issue":"2","key":"i2168-9709-15-6-315-b15","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"163","article-title":"Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo","volume":"267","author":"Baandrup","year":"2017","unstructured":"Baandrup L,\nFagerlund B,\nGlenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163-71. DOI: 10.1007\/s00406-016-0711-8"},{"issue":"1","key":"i2168-9709-15-6-315-b16","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"17","article-title":"Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set","volume":"268","author":"Fond","year":"2018","unstructured":"Fond G,\nBerna F,\nBoyer L,\nGodin O,\nBrunel L,\nAndrianarisoa M, et al. Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci. 2018;268(1):17-26. DOI: 10.1007\/s00406-017-0787-9"},{"key":"i2168-9709-15-6-315-b17","series-title":"Eur Psychiatry","first-page":"50","article-title":"Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966","volume":"45","author":"Hulkko","year":"2017","unstructured":"Hulkko AP,\nMurray GK,\nMoilanen J,\nHaapea M,\nRannikko I,\nJones PB, et al. Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966. Eur Psychiatry. 2017;45:50-8. DOI: 10.1016\/j.eurpsy.2017.06.004"},{"issue":"3","key":"i2168-9709-15-6-315-b18","series-title":"Clin Neuropharmacol","first-page":"89","article-title":"Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders\u2014associations with cognition and global functioning","volume":"44","author":"Savi\u0107","year":"2021","unstructured":"Savi\u0107 B,\nJeroti\u0107 S,\nRisti\u0107 I,\nZebi\u0107 M,\nJovanovi\u0107 N,\nRusso M, et al. Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders\u2014associations with cognition and global functioning. Clin Neuropharmacol. 2021;44(3):89-93. DOI: 10.1097\/WNF.0000000000000442"},{"issue":"3","key":"i2168-9709-15-6-315-b19","series-title":"PCN Rep","first-page":"e42","article-title":"Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia","volume":"1","author":"Oyama","year":"2022","unstructured":"Oyama H,\nOda K,\nMatsuo R. Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia. PCN Rep. 2022;1(3):e42. DOI: 10.1002\/pcn5.42"},{"key":"i2168-9709-15-6-315-b20","series-title":"Schizophr Res","first-page":"118","article-title":"Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia","volume":"266","author":"M\u00e4kipelto","year":"2024","unstructured":"M\u00e4kipelto V,\nTuulio-Henriksson A,\nHakulinen C,\nNiemel\u00e4 S,\nL\u00e4hteenvuo M,\nWegelius A, et al. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia. Schizophr Res. 2024;266:118-26. DOI: 10.1016\/j.schres.2024.02.025"},{"issue":"11","key":"i2168-9709-15-6-315-b21","series-title":"Cochrane Database Syst Rev","first-page":"CD006391","article-title":"Benzodiazepines for schizophrenia","volume":"11","author":"Dold","year":"2012","unstructured":"Dold M,\nLi C,\nTardy M,\nKhorsand V,\nGillies D,\nLeucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11(11):CD006391. DOI: 10.1002\/14651858.CD006391.pub2"},{"issue":"9","key":"i2168-9709-15-6-315-b22","series-title":"Eur Neuropsychopharmacol","first-page":"1023","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","unstructured":"Dold M,\nLi C,\nGillies D,\nLeucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol. 2013;23(9):1023-33. DOI: 10.1016\/j.euroneuro.2013.03.001"},{"issue":"12","key":"i2168-9709-15-6-315-b23","series-title":"Cochrane Database Syst Rev","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"12","author":"Zaman","year":"2017","unstructured":"Zaman H,\nSampson SJ,\nBeck AL,\nSharma T,\nClay FJ,\nSpyridi S, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017;12(12):CD003079. DOI: 10.1002\/14651858.CD003079.pub4"},{"key":"i2168-9709-15-6-315-b24","series-title":"Schizophr Bull","first-page":"sbae098","article-title":"Comparative efficacy and acceptability of treatment strategies for antipsychotic-induced akathisia: a systematic review and network meta-analysis","author":"Furukawa","year":"2024","unstructured":"Furukawa Y,\nImai K,\nTakahashi Y,\nEfthimiou O,\nLeucht S. Comparative efficacy and acceptability of treatment strategies for antipsychotic-induced akathisia: a systematic review and network meta-analysis. Schizophr Bull. 2024:sbae098. DOI: 10.1093\/schbul\/sbae098"},{"issue":"6","key":"i2168-9709-15-6-315-b25","series-title":"J Clin Psychopharmacol","first-page":"403","article-title":"Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study","volume":"9","author":"Kutcher","year":"1989","unstructured":"Kutcher S,\nWilliamson P,\nMacKenzie S,\nMarton P,\nEhrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1989;9(6):403-6. PMID: 2574191"},{"issue":"3","key":"i2168-9709-15-6-315-b26","series-title":"Clin Neuropharmacol","first-page":"236","article-title":"A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia","volume":"17","author":"Pujalte","year":"1994","unstructured":"Pujalte D,\nBotta\u00ef T,\nHu\u00eb B,\nAlric R,\nPouget R,\nBlayac JP, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236-42. DOI: 10.1097\/00002826-199406000-00003"},{"issue":"1-3","key":"i2168-9709-15-6-315-b27","series-title":"Schizophr Res","first-page":"255","article-title":"Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset","volume":"169","author":"Berna","year":"2015","unstructured":"Berna F,\nMisdrahi D,\nBoyer L,\nAouizerate B,\nBrunel L,\nCapdevielle D, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015;169(1-3):255-61. DOI: 10.1016\/j.schres.2015.10.040"},{"issue":"1","key":"i2168-9709-15-6-315-b28","series-title":"Cochrane Database Syst Rev","first-page":"CD000205","article-title":"Benzodiazepines for antipsychotic-induced tardive dyskinesia","volume":"1","author":"Bergman","year":"2018","unstructured":"Bergman H,\nBhoopathi PS,\nSoares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000205. DOI: 10.1002\/14651858.CD000205.pub3"},{"issue":"8","key":"i2168-9709-15-6-315-b29","series-title":"Cochrane Database Syst Rev","first-page":"CD006570","article-title":"Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses","volume":"8","author":"Zaman","year":"2019","unstructured":"Zaman H,\nGibson RC,\nWalcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Cochrane Database Syst Rev. 2019;8(8):CD006570. DOI: 10.1002\/14651858.CD006570.pub3"},{"issue":"5","key":"i2168-9709-15-6-315-b30","series-title":"Neurology","first-page":"463","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R,\nFahn S,\nWeiner WJ,\nGronseth GS,\nSullivan KL,\nZesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-9. DOI: 10.1212\/WNL.0b013e31829d86b6. Erratum in: Neurology. 2013;81(22):1968. PMID: 23897874"},{"key":"i2168-9709-15-6-315-b31","series-title":"J Neurol Sci","first-page":"67","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R,\nJitkritsadakul O,\nFriedman JH,\nFahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75. DOI: 10.1016\/j.jns.2018.02.010"},{"issue":"4","key":"i2168-9709-15-6-315-b32","series-title":"J Psychopharmacol","first-page":"327","article-title":"Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology","volume":"37","author":"Rogers","year":"2023","unstructured":"Rogers JP,\nOldham MA,\nFricchione G,\nNorthoff G,\nEllen Wilson J,\nMann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327-69. DOI: 10.1177\/02698811231158232"},{"issue":"5","key":"i2168-9709-15-6-315-b33","series-title":"Aust N Z J Psychiatry","first-page":"410","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","unstructured":"Galletly C,\nCastle D,\nDark F,\nHumberstone V,\nJablensky A,\nKillackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-72. DOI: 10.1177\/0004867416641195"},{"issue":"9","key":"i2168-9709-15-6-315-b34","series-title":"Can J Psychiatry","first-page":"604","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","unstructured":"Remington G,\nAddington D,\nHoner W,\nIsmail Z,\nRaedler T,\nTeehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604-16. DOI: 10.1177\/0706743717720448"},{"issue":"1","key":"i2168-9709-15-6-315-b35","series-title":"J Psychopharmacol","first-page":"3","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","unstructured":"Barnes TR,\nDrake R,\nPaton C,\nCooper SJ,\nDeakin B,\nFerrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. DOI: 10.1177\/0269881119889296"},{"issue":"9","key":"i2168-9709-15-6-315-b36","series-title":"Am J Psychiatry","first-page":"868","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","unstructured":"Keepers GA,\nFochtmann LJ,\nAnzia JM,\nBenjamin S,\nLyness JM,\nMojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-72. DOI: 10.1176\/appi.ajp.2020.177901"},{"issue":"1","key":"i2168-9709-15-6-315-b37","series-title":"Harv Rev Psychiatry","first-page":"18","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","author":"Osser","year":"2013","unstructured":"Osser DN,\nRoudsari MJ,\nManschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013;21(1):18-40. DOI: 10.1097\/HRP.0b013e31827fd915"},{"issue":"1","key":"i2168-9709-15-6-315-b38","series-title":"Eur Psychiatry","first-page":"e57","article-title":"European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia","volume":"65","author":"Vita","year":"2022","unstructured":"Vita A,\nGaebel W,\nMucci A,\nSachs G,\nBarlati S,\nGiordano GM, et al. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65(1):e57. DOI: 10.1192\/j.eurpsy.2022.2315"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/6\/article-p315.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/6\/article-p315.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/6\/article-p315.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:51:29Z","timestamp":1770771089000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/6\/article-p315.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":76,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2025.12.315","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}